GLPwatch
Alcohol use disorder
Investigational / off-label
Last updated 2026-05-28 15:46 UTCResearch on semaglutide, a GLP-1 analogue, indicates it reduces alcohol consumption and modulates central GABA neurotransmission in animal models.
AI summary of the sources below.
Approved GLP-1 drugs (0)
No GLP-1 drug is FDA-approved for alcohol use disorder in our data. Any research below reflects investigational or off-label study.
Research (50)
- Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
- Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.
- The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents.
- Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward.
- The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.
- The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice.
- Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.
- The benefits of GLP-1 drugs beyond obesity.
- The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents.
- Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats.
- Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.
- Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.
- Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.
- The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice.
- Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats.
- Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys.
- Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents.
- Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors.
- Effects of dulaglutide on alcohol consumption during smoking cessation.
- Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.
- Effects of the GLP-1 Agonist Exendin-4 on Intravenous Ethanol Self-Administration in Mice.
- The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis.
- Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series.
- Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents.
- Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1.
- Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
- Brain Site-Specific Inhibitory Effects of the GLP-1 Analogue Exendin-4 on Alcohol Intake and Operant Responding for Palatable Food.
- The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.
- Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.
- Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats.
Common questions
- Which GLP-1 drugs are FDA-approved for Alcohol use disorder?
- No GLP-1 drug is currently FDA-approved for alcohol use disorder; any use would be off-label or investigational.
- Is there research on GLP-1 drugs for Alcohol use disorder?
- GLPwatch tracks 76 research papers on GLP-1 drugs and alcohol use disorder. This research is investigational and does not imply FDA approval.